<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04672265</url>
  </required_header>
  <id_info>
    <org_study_id>19/218</org_study_id>
    <secondary_id>213396</secondary_id>
    <nct_id>NCT04672265</nct_id>
  </id_info>
  <brief_title>Increasing Access to Breast Cancer Screening Among Immigrants</brief_title>
  <official_title>A Randomized Trial to Increase Access to Breast Cancer Screening by Invitation Language Among Immigrants in Norway</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to test whether inviting immigrants to breast cancer screening with a&#xD;
      letter in their mother tongue in addition to the standard letter in Norwegian changes&#xD;
      screening uptake in these immigrant groups, compared with a comparable group who receive the&#xD;
      invitation in Norwegian only,&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women in selected immigrant groups according to birth country will be invited to screening&#xD;
      and randomized in a 1:1 ratio to receive the screening invitation and information material 1)&#xD;
      in the major official native language in the country the invitee is born in addition to&#xD;
      Norwegian (intervention group), or 2) only Norwegian (control). The 13 selected countries of&#xD;
      origin are Poland, the Philippines, Pakistan, Somalia and Arabic speaking countries (Iraq,&#xD;
      Syria, Morocco, Lebanon, Algeria, Egypt, Palestine, Sudan and Tunisia). The five intervention&#xD;
      languages will thus be Polish, English, Urdu, Somali and Arabic.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 15, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2030</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants are randomized to receive the invitation in the major official native language in the country the participant is born and Norwegian, or in Norwegian only, consecutively when it is their turn to be invited to screening.</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>The screening invitees randomized to the control group are not informed about this study. They receive &quot;care as usual&quot;, the screening invitation letter in Norwegian language.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Screening attendance</measure>
    <time_frame>0-6 months after sent screening invitation letter</time_frame>
    <description>Attendance in breast cancer screening programme (yes/no)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15800</enrollment>
  <condition>Cancer Screening</condition>
  <arm_group>
    <arm_group_label>Mother tongue and Norwegian</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Written material related to screening sent to the invitee in two languages.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Norwegian</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Written material related to screening sent to the invitee in Norwegian only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Mother tongue and Norwegian</intervention_name>
    <description>The screening invitation letter, the information leaflet, the reminder letter and the result letter will be sent in two languages; an official language in the country where the invitee is born, and Norwegian.</description>
    <arm_group_label>Mother tongue and Norwegian</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Invited to screening program during the study recruitment period (January 2021-June&#xD;
             2022)&#xD;
&#xD;
          -  The registered country of birth of the invitee is one of the following; Poland,&#xD;
             Pakistan, Philippines, Somalia, Iraq, Syria, Morocco, Lebanon, Algeria, Egypt,&#xD;
             Palestine, Sudan and Tunisia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not reached with the screening invitation letter because of wrong address or similar&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>48 Years</minimum_age>
    <maximum_age>73 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paula Berstad, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Registry of Norway</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paula Berstad, PhD</last_name>
    <phone>+4722928735</phone>
    <email>paula.berstad@kreftregisteret.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Solveig Hofvind, PhD</last_name>
    <phone>+4722928828</phone>
    <email>solveig.hofvind@kreftregisteret.no</email>
  </overall_contact_backup>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 16, 2020</study_first_submitted>
  <study_first_submitted_qc>December 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Paula Berstad</investigator_full_name>
    <investigator_title>Researcher</investigator_title>
  </responsible_party>
  <keyword>cancer screening</keyword>
  <keyword>breast cancer</keyword>
  <keyword>non-native</keyword>
  <keyword>immigrant</keyword>
  <keyword>participation rate</keyword>
  <keyword>invitation</keyword>
  <keyword>information</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

